10 Best European Growth Stocks to Buy

7. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

On May 7, 2026, Morgan Stanley analyst Sean Laaman raised the firm’s price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $245 from $226 while maintaining an Overweight rating on the shares.

Raymond James analyst Tiago Fauth also raised the firm’s price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $239 from $227 and maintained an Outperform rating on the shares. The firm noted that Jazz shares have risen about 25% year-to-date as investors increasingly view the company as transitioning from a specialty pharmaceutical business toward a more innovation-driven biotech profile. Raymond James pointed specifically to the competitive clinical data and priority review status for zanidatamab in first-line gastroesophageal adenocarcinoma as an important driver of that shift in perception.

On May 5, 2026, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported Q1 adjusted EPS of $6.34, well above the consensus estimate of $4.66. GAAP EPS came in at $4.43. Revenue totaled $1.07B, ahead of the consensus estimate of $979.01M. President and CEO Renee Gala said the company delivered strong first-quarter results supported by disciplined execution across the business, alongside continued pipeline progress. Gala highlighted sustained demand for Xywav, growing momentum from the company’s rare oncology launches, including Modeyso and Zepzelca in first-line extensive-stage small cell lung cancer, and continued growth from Epidiolex. Management also pointed to the potential launch of zanidatamab in first-line gastroesophageal adenocarcinoma later this year as an important upcoming catalyst as Jazz continues advancing its pipeline and broader business development strategy.

Jazz Pharmaceuticals maintained its full-year 2026 revenue guidance range of $4.25B to $4.5B, compared to the consensus estimate of $4.45B.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) develops and commercializes therapies focused on neuroscience and oncology markets globally.